Hopstem Biotechnology Co., Ltd.’s Post

We are thrilled to celebrate the recent announcement of a nearly $200-million partnership between Aspect Biosystems and the Government of British Columbia and Government of Canada! As early investors in Aspect Biosystems through our I² Program, Genome BC is proud to witness this incredible milestone. This partnership will create over 200 high-quality jobs and advance the development of cutting-edge bioprinted tissue therapeutics, revolutionizing treatment options for people in B.C. and around the world.                                                                   Aspect Biosystems' pioneering work in bioprinted tissue therapeutics represents a major step forward in regenerative medicine. This investment will help establish clinical biomanufacturing capabilities, advance technology, and expand their therapeutic pipeline for diseases like diabetes, obesity and liver disease. We are excited to continue supporting Aspect Biosystems and the thriving life sciences sector in B.C. Learn more about this partnership and the future of bioprinted tissue therapeutics. https://lnkd.in/gq2sSBCH #AspectBiosystems #RegenerativeMedicine #Biomanufacturing #JobsBC

As any scientist will know, our basic tools are pipettes. Its something that scientists get very attached to, and everyone has their favourites!! We love the INTEGRA Biosciences pipettes and when we won a startup prize, we were ecstatic. They are so easy to use, tips fit snug and importantly we have separated our workflows with different set of pipettes really limiting our cross contamination. Enabling us to work swiftly, and really helping us progress. #antibodytherapeutics #antibodydiscovery #curecancer #startup

Join us at the Galien Forum USA 2024 for an enlightening panel on Big Biotech! 🌟 We're honored to welcome an esteemed group of experts who are shaping the future of biotechnology: 🔬 Phillip Sharp - 1993 Nobel Laureate for Physiology or Medicine, Institute Professor and Biology Emeritus at MIT's MIT MIT Koch Institute for Integrative Cancer Research, and Co-Chair of the Galien Forum (Panel Chair). 🔬 Jay Bradner - Executive Vice President, Research & Development and Chief Scientific Officer, Amgen (Panelist). 🔬 Pushkal Garg - Chief Medical Officer and Executive Vice President, Development & Medical Affairs, Alnylam Pharmaceuticals (Panelist). 🔬 Jane Grogan - Executive Vice President and Head of Research, Biogen (Panelist). 🔬 george yancopoulos - Board Co-Chair, President & Chief Scientific Officer, Regeneron Pharmaceuticals (Panelist). Dive into groundbreaking discussions, innovative ideas, and future-forward insights with leaders at the forefront of biotech research and development. 👉 Watch out for the newsletter coming out soon for more details! #GalienForum #BigBiotech #Innovation #Biotechnology #Healthcare #ResearchAndDevelopment #BiotechLeaders #FutureOfHealth #MedicalInnovation

A big day at Juvena Therapeutics, as their lead candidate, JUV-161, has received positive FDA feedback and Orphan Disease Designation (ODD) for the treatment of Myotonic Dystrophy Type 1 (DM1). This is a major win for the broader ecosystem as an example of how founder-led biotech can truly change how we think of addressing unmet medical needs. As an early investor, I take immense pride in the team's dedicated efforts over the course of five and a half years, involving hard work and determination, to establish a world-class, fully integrated platform for the discovery and development of biologics. Their unique approach to repairing and restoring muscle health with a biologic that enhances muscle regeneration, metabolism, and function, countering the effects of aging and degenerative disease. Congrats Hanadie Yousef, Jeremy O'Connell, Neil Berkley, Mo Tabrizi, all the scientists, biologists, engineers, rest of the team, other investors, and the many partners who have believed in this group. Big things ahead!!! 🚀 Link to the announcement: https://lnkd.in/gvRTC2NS #biotech #venturecapital #founderled #healthcare #MyotonicDystrophy #RareDisease #unmetmedicalneed #healthspan #sarcopenia

Last month, Imagine Pharma's Dr. Rita Bottino moderated the "Xenotransplantation’s regulatory road to the clinic" session at the 30th Congress of The Transplantation Society (TTS) in Istanbul. The session included presentations by Wayne John Hawthorne, Efstratios (Stratos) Chatzixiros, and Leo Hans Buhler. The session explored the pioneering efforts that have shaped the landscape of xenotransplantation, from its inception to current breakthroughs. Additionally, the session provided valuable insights into the challenges and opportunities in continuing the registration of clinical xenotransplantation, paving the way for its widespread implementation. #Xenotransplantation #BioTech #RegenerativeMedicine #ImaginePharma #TTS2024

Integrating The 3Rs Collaborative (3RsC) is in line with our values for changing the dogmas of animal 🐀 usage during the drug development process 💊 . We are convinced that PredictCan Biotechnologies cell educating technology can strongly contribute to reduce animal usage. Many thanks to Clive Roper BSc PhD CBiol CSci ERT FRSB and Megan LaFollette for their help to joining the 3Rs community. #Predictcan #3R #animal #precisionmedicine

-GSK announces appointment of Dr. Jeannie Lee, renowned for her groundbreaking work in RNA biology and drug development, to its Board of Directors. -Dr. Lee's extensive experience in academia and biotech entrepreneurship, including co-founding Translate Bio and Fulcrum Therapeutics, enhances GSK's strategic vision in scientific innovation. -Sir Jonathan Symonds, Chair of GSK, expresses enthusiasm for Dr. Lee's appointment, citing her expertise in RNA biology and epigenetics as invaluable assets aligning with GSK's research priorities. To know more, read the full article on #theenterprise #GSK #JeannieLee #BoardAppointment #RNA Biology #BiotechInnovation#globalbusiness #theenterprisenews #followformore #global #finance

"Our approach at Ultragenyx has been to streamline the drug development process, making it faster and more cost-efficient. This optimization involves designing studies that allow us to make scientific leaps, thereby reducing the development time from the typical 10-12 years to just 3-5 years." Emil Kakkis, CEO and President at Ultragenyx This interview is part of our #Newsweek special feature, “ The New Era of Life Sciences". https://lnkd.in/gzcP3JwE

Get ready to embrace curiosity in just 2 weeks! At this year's #SwissBiotechDay, hosted by the esteemed Swiss Biotech Association and renowned as one of Europe's premier #biotechnology #conferences, Bavarian Biotech is set to take center stage at the 🏘️ #globalvillage. The Swiss Biotech Day serves as a nexus for professionals within the 🌎global #lifesciences community, drawing in experts from diverse backgrounds. In 2024, it promises yet another immersive experience, offering a fertile ground for #networking, thought-provoking discussions, and the exploration of cutting-edge advancements across various domains such as #R&D, manufacturing, data management, #artificialintelligence, and innovative #financing. We extend a warm invitation for you to connect with the Biotech companies from #Bavaria featured in this year's #BioMdelegation. Join us as we embark on this journey, with the following #pioneers on board: 👉 FGK Clinical Research GmbH: A full service contract #research organisation (#CRO) offering a complete range of clinical development and consulting services to pharmaceutical, biotechnology and #medicaldevice companies. 👉 Iris Biotech GmbH provides scientists in both industry and academia with innovative and rare #compounds, standard consumables and unusual building blocks i.e. required for the modification of #peptides. 👉 Cfm Oskar Tropitzsch GmbH assists the chemical, #pharmaceutical and biotechnological industry in sourcing and producing #chemical specialties – with the right documentation, the correct quantity from mg to mt and proper quality. 👉 Cortex Discovery’s in silico #drugdiscovery platform is based on its leading-edge #AI technology which can predict molecule properties in all therapeutic fields. Cortex’s comprehensive services cover the entire spectrum of preclinical #drugdevelopment, from #HitDiscovery to #LeadOptimization. 👉 Velvio GmbH develops new medicines to restore organ repair functions for treatment in #Neurodegeneration and Pulmonary Fibrosis, first in #Orphandiseases Amyotrophic Lateral Sclerosis (ALS) and Idiopathic pulmonary Fibrosis (IPF). Furthermore, Velvio targets to enhance clinical responses of solid tumors to #Immune-#Oncology treatment concepts. We are looking forward to meeting you in #Basel! #swissbiotechday2024

We're proud to add Alpha Cognition, Inc. (CNSX: $ACOG) to the roster of quality presenting companies at the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. Alpha Cognition, Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative disease, such as Alzheimer’s disease and Cognitive Impairment with mild Tramautic Brain Injury (“mTBI”). The Company’s first product ZUNVEYL is approved by the U.S. Food and Drug Administration (FDA) as a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Alpha Cognition, Inc. initiatives are spearheaded by Denis Kay, Phillip Mertz, Michael Mcfadden, and Don Kalkofen. Conference attendees will have the unique opportunity to engage directly with Alpha Cognition, Inc. executives, gaining valuable insights into the company’s development in novel treatments for under-served neurodegenerative diseases. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital who made this event possible: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. Spartan Capital Securities, LLC is a full-service, integrated financial services firm trusted by high-net-worth individuals and institutions for sound investment guidance. We focus on understanding our clients' objectives and executing strategies to meet their financial goals. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #AlphaCognition #ACOG #biopharmaceutical